Targeting vesicle trafficking: An important approach to cancer chemotherapy

Recent Patents on Anti-Cancer Drug Discovery

Volumn 3, Issue 2, 2008, Pages 137-147

  Wright, Paul K ^a,b  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

^b MANCHESTER ROYAL INFIRMARY   (United Kingdom)

Author keywords

Angiogenesis; Cancer; Chemotherapy; Endocytosis; Exocytosis; Exosome; Invasion; Membrane vesicle; Metastasis; Microparticle; Microvesicle; Multidrug resistance; Rab; Secretion; Vesicle; Vesicle trafficking

Indexed keywords

ANTINEOPLASTIC AGENT; BECLIN 1; BREAST CANCER RESISTANCE PROTEIN; CAVEOLIN 1; CHEMOKINE RECEPTOR CXCR4; CLATHRIN; CLAUDIN 7; CURCUMIN; DOXORUBICIN; DYNAMIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FAS LIGAND; FIBROBLAST GROWTH FACTOR 2; GELATINASE A; GELATINASE B; LIM KINASE 1; PACLITAXEL; PROTON PUMP INHIBITOR; RAB PROTEIN; RAB27A PROTEIN; RAC PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; SPHINGOMYELIN; SPHINGOMYELIN PHOSPHODIESTERASE INHIBITOR; SYNTAXIN; THROMBOPLASTIN; TRASTUZUMAB; UNINDEXED DRUG; UROKINASE; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; BLADDER CARCINOMA; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RESISTANCE; CARCINOGENESIS; CELL CYCLE REGULATION; CELL MIGRATION; CELL ORGANELLE; CELL VACUOLE; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SENSITIVITY; DRUG TARGETING; ENDOCYTOSIS; EXOCYTOSIS; EXOSOME; GENE EXPRESSION; HEMATOLOGIC MALIGNANCY; HUMAN; LIVER CELL CARCINOMA; MELANOMA; METASTASIS; MULTIDRUG RESISTANCE; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; SYSTEMIC DISEASE; TUMOR IMMUNITY; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL AVAILABILITY; BIOLOGICAL TRANSPORT; DRUG RESISTANCE, NEOPLASM; ENDOCYTOSIS; EXOCYTOSIS; HUMANS; NEOPLASMS; TRANSPORT VESICLES;

EID: 55649095073     PISSN: 15748928     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489208784638730     Document Type: Review

References (118)

1. Kumar V, Abbas AK, Fausto N. In: Robbins and Cotran Pathologic basis of disease 7th Ed.: Neoplasia. Philadelphia, Elsevier Saunders. 2005; 269-342.
2. Burgoyne RD, Morgan A. Secretory granule exocytosis. Physiol. Rev 2003; 83: 581-632.
3. Aridor M, Hannan LA. Traffic Jams II: An update of diseases of intracellular transport. Traffic 2002; 3: 781-790.
4. Chan AM, Weber T. A putative link between exocytosis and tumour development. Cancer Cell 2002; 2: 427-428.
5. Polo S, Pece S, Di Fiore PP. Endocytosis and cancer. Curr Opin Cell Biol 2004; 16: 156-161.
6. Jordens I, Marsman M, Kuijl C, Neetjes J. Rab proteins, connecting transport and vesicle fusion. Traffic 2005; 6: 1070-1077.
7. Yoon S, Shin S, Mercurio AM. Hypoxia stimulates carcinoma invasion by stabilizing and promoting Rab11 trafficking of α6β4 integrin. Cancer Res 2005; 65: 2761-2769.
8. Liu YJ, Wang O, Li W, et al. Rab23 is a potential biological target for treating hepatocellular carcinoma. World J Gastroenerol 2007; 13: 1010-1017.
9. Hillman, J.L., Guegler, K.J.: US20006010859 (2000). 10 Mor O, Nativ O, Stein A, et al. Molecular analysis of transitional cell carcinoma using cDNA microarray. Oncogene 2003; 22: 7702-7710.
10. Shibata D, Mori Y, Cai K, et al. RAB32 hypermethylation and microsatellite instability in gastric and endometrial carcinomas. Int J Cancer 2006; 119: 801-806.
11. Stein M, Dong J, Wandinger-Neas A. Rab proteins and endocytic trafficking: potential targets for therapeutic intervention. Adv Drug Delivery Rev 2003; 55: 1421-1437.
12. Montrel V, Huang T, Mose E, Pesonjamasp K, Tarin D. Expression profiling of primary tumours and matched lymphatic and lung metastases in a xenogeneic breast cancer model. Am J Path 2005; 166: 1565-1579.
13. Cheng KW, Lahad JP, Kuo W, et al. The RAB25 small GTPase determines aggressiveness of ovarian and breast cancers. Nat Med 2004; 10: 1251-1256.
14. Cheng KW, Lahad JP, Gray JW, Mills GB. Emerging role of RAB GTPases in cancer and human disease. Cancer Res 2005; 65: 2516-2519.
15. Hillman, J.L., Goli, S.K., Bandman, O.: US5869291 (1999).
16. Johnson JL, Ellis BA, Noack D, Seabra MC, Catz SD. The Rab27a-binding protein, JFC1, regulates the androgen-dependent secretion of prostate-specific antigen and prostate-specific acid phosphatase. Biochem J 2005; 391: 699-710.
17. Hillman, J.L., Lal, P., Corley, N., Shah, P.: US2001600472 (2001).
18. Tan C, Li J, Wang J, Xiang Q, et al. Proteomic analysis of differential protein expression in human nasopharyngeal carcinoma cells induced by NAG7 transfection. Proteomics 2002; 2: 306-312.
19. Mori Y, Yin j, Sato F, et al. Identification of genes uniquely involved in frequent microsatellite instability colon carcinogenesis by expression profiling combined with epigenetic scanning. Cancer Res 2004; 64: 2434-2438.
20. Nishimura N, Goji J, Nakamura H, Orita S, Takai Y, Sano K. Cloning of a brain-type isoform of human Rab GDI and its expression in human neuroblastoma cell lines and tumour specimens. Cancer Res 1995; 55: 5445-5450.
21. He H, Dai f, Vu L, et al. Identification and characterization of nine novel human small GTPases showing variable expressions in liver cancer tissues. Gene Expr 2002; 10: 231-242.
22. He XH, Li JJ, Xie YH, et al. Altered gene expression profiles of NIH3T3 cells regulated by human lung cancer associated gene CT12O. Cell Res 2004; 14: 487-496.
23. Wells SI, Aronow BJ, Wise TM, Williams SS, Couget JA, Howley PM. Transcriptome signature of irreversible senescence in human papilloma virus-positive cervical cancer cells. Proc Natl Acad sci USA 2003; 100: 7093-7098.
24. Vadlamudi RK, Wang R, Talukdur AH, Adam L, Johnson R, Kumar R. Evidence of Rab3A expression, regulation of vesicle trafficking, and cellular secretion in response to heregulin in mammary epithelial cells. Mol Cell Biol 2000; 20: 9092-9101.
25. Gez S, Crossett B, Christopherson R. Differentially expressed cytosolic proteins in human leukemia and lymphoma cell lines correlate with lineages and functions. Biochem Biophys Acta 2007; 1774: 1173-1183.
26. Amillet JM, Ferbus D, Real FX, et al. Characterization of human Rab20 overexpressed in exocrine pancreatic carcinoma. Hum Pathol 2006; 37: 256-263.
27. Caswell PT, Spence HJ, Parsons M, et al. Rab25 associates with α5β1 integrin to promote invasive migration in 3D microenvironments. Dev Cell 2007; 13: 496-510.
28. Calvo A, Xiao N, Kang, et al. Alteration in gene expression profiles during prostate cancer progression: functional correlations to tumourigenicity and downregulation of selenoprotein-P in mouse and human tumours. Cancer Res 2002; 62: 5325-5335.
29. Mori T, Fukuda Y, Koroda H, et al. Cloning and characterization of a novel Rab-family gene, Rab36, within the region at 22q11.2 that is homozygously deleted in malignant rhabdoid tumours. Biochem Biophys Res Commun 1999; 254: 594-600.
30. Hillman, J.L., Lal, P., Corley, N., Shah, P.: EP1007695/US20015892012. (2000).
31. Bandman, O., Au-Young, J.: US20006124116 (2000).
32. Hillman, J.L., Guegler, KJ.: US5843717 (1998).
33. Fukui K, Tamura S, Wada A, et al. Expression of Rab5a in hepatocellular carcinoma: Possible involvement in epidermal growth factor signaling. Hepatol Res 2007; 37: 957-965.
34. Jayachandram G, Sazaki J, Nishizaki M, et al. Fragile histidine triad-mediated tumour suppression of lung cancer by targeting multiple components of Ras/Rho GTPase molecular switch. Cancer Res 2007; 67: 10379-10388.
35. Dowling P, O'Driscoll L, Meleady P, et al. 2-D Difference gel electrophoresis of the lung squamous cell carcinoma versus normal sera demonstrates consistent alterations in the levels of ten specific proteins. Electrophoresis 2007; 28: 4302-4310.
36. Bravo-Cordero JJ, Marrero-Diaz H, Megiaz D, et al. MT1-MMP preinvasive activity is regulated by a novel Rab8-dependent exocytic pathway. EMBO J 2007; 26: 1499-1510.
37. Palmieri D, Bouadis A, Ronchetti H, Merino MJ, Steeg PS. Rab11a differentially modulates epidermal growth factor-induced proliferation and motility in immortal breast cells. Breast Cancer Res Treat 2006; 100: 127-137.
38. Gebhardt C, Breitenbach U, Richter KH, et al. c-Fos-dependent induction of the small ras-related GTPase Rab11a in skin carcinogenesis. Am J Pathol 2005; 167: 243-253.
39. Graff L, Castrop F, Bauer M, Hofler H, Gratzl M. Expression of vesicular monoamine transporters, synaptosomal-associated protein 25 and syntaxin1: a signature of human small cell lung carcinoma. Cancer Res 2001; 61: 2138-2144
40. Watahiki A, Waki K, Hayatsu N, et al. Libraries enriched for alternatively spliced exons reveal splicing patterns in melanocytes and melanomas. Nature Methods 2004; 1: 233-239.
41. Katkoori VR, Jia X, Chatla C, et al. Clinical significance of novel single nucleotide polymorphism in te 5′ untranslated region of the Rabphillin-3A-like gene in colorectal adenocarcinoma. Front Biosci 2008; 13: 1050-1061.
42. Camonis JH, White MA. Ral GTPases: corrupting the exocyst in cancer cells. Trends Cell Biol 2005; 15: 327-332.
43. Edinger AL, Thompson CB. Defective autophagy leads to cancer. Cancer Cell 2003; 4: 422-424.
44. Pei L, Peng Y, Yang Y, et al. PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res 2002; 62: 5420-5424.
45. Kartmann B, Roth D. Novel roles for mammalian septins: from vesicle trafficking to oncogenesis. J Cell Sci 2001; 114: 839-844.
46. Luo, Y.: EP1161442 and WO010043419 (2001).
47. Egan, S.E., Wang, W., Sengar, A.: US20067118886 (2006).
48. Prescot JL, Tindall DJ. Clathrin gene expression is androgen regulated in the prostate. Endocrinology 1998; 139: 2111-2119.
49. Blackman B, Russell T, Nordeen SK, Medina D, Neville MC. Claudin 7 expression and localization in the normal murine mammary gland and murine mammary tumours. Breast Cancer Res 2005; 7: R248-R255.
50. Cohen AW, Hnasko R, Schubert W, Lisanti MP. Role of caveolae and caveolins in health and disease. Physiol Rev 2004; 84: 1341-1379.
51. Kartmann B, Roth D. Novel roles for mammalian septins: from vesicle trafficking to oncogenesis. J Cell Sci 2001; 114: 839-844.
52. Blanes, M., Llobregat, H.,Gil, T., Fernandez, B., Planell, C., Ferrer, M., Viniegra, B., Gutierrez, P., Carbonell, C., Perez, P.: WO00064932 (2000). 54 Rao DS, Hyun TS, Kumar PD, et al. Huntingtin-interacting protein 1 is overexpressed in prostate and colon cancer and is critical for cellular survival. J Clin Invest 2002; 110: 351-360.
53. Nguyen LN, Holdren MS, Nguyen AP, et al. Sorting Nexin 1 Down-Regulation Promotes Colon Tumourigenesis. Clin Cancer Res 2006; 12: 6952-6959.
54. Fuchs U, Rehkamp G, Hass OA, et al. The human formin-binding protein 17 (FBP17) interacts with sorting nexin, SNX2, and is an MLL-fusion partner in acute myelogenous leukaemia. PNAS 2001; 98: 8756-8761.
55. Osman I, Bajorin DF, Sun T, et al. Novel blood biomarkers of human urinary bladder cancer. Clin Cancer Res 2006; 12: 3374-3380.
56. Magnusson MK, Meade KE, Browne KE, et al. Rabaptin-5 is a novel fusion partner to platelet-derived growth factor beta receptor in chronic myelomonocytic leukaemia. Blood 2001; 98: 2518-2525.
57. Sreenath AS, Kumar KR, Reddy GV, et al. Evidence for the association of Synaptotagmin with glutathione S-transferases: Implications for a novel function in human breast cancer. Clin Biochem 2005; 38: 436-443.
58. Hu-Liekovan S, Zhang J, Wu L, Shimada H, Schofield DE, Triche TJ. EWS-FLI1 fusion protein up-regulates critical genes in neural crest development and is responsible for the observed phenotype of Ewing's family of tumours. Cancer Res 2005; 65: 4633-4644.
59. David P, el Far O, Marin-Mouto N, Poupon MF, Takahashi M, Seagar MJ. Expression of Synaptotagmin and syntaxin associated with N-type calcium channels in small cell lung cancer. FEBS Lett 1993; 326: 135-139.
60. Nishimura Y, Yoshioka K, Bernard O, Himeno M, Itoh K. LIM kinase 1: evidence for a role in the regulation of intracellular vesicle trafficking of lysosomes and endosomes in human breast cancer cells. Eur J Cell Biol 2004; 83: 369-380.
61. Rubin MA, Varambally S, Beroukhim R, et al. Overexpression, amplification, and androgen regulation of TPD52 in prostate cancer. Cancer Res 2004; 64: 3814-3822.
62. Friedmann E, Salzberg Y, Weinberger A, Shaltiel S, Gerst JE. YOS9, the putative yeast homolog of a gene amplified in osteosarcomas, is involved in the ER-Golgi transport of GPI-anchored proteins. J Biol Chem 2002; 277: 35274-35281.
63. Palmer RE, Lee SB, Wong JC, et al. Induction of BAIAP3 by the EWS-WT1 chimeric fusion implicates regulated exocytosis in tumourigenesis. Cancer Cell 2002; 2: 497-505.
64. Ll, J., Powers, S., Xiang, P., Peng, Y.: EP1364067 (2003)/ WO02062959. (2002).
65. Ito E, Honma R, Imai J, et al. A tetraspanin-family protein, T-cell acute lymphoblastic leukemia-associated antigen 1, is induced by the Ewing's sarcoma-Wilms' tumour 1 fusion protein of desmoplastic small round-cell tumour. Am J Pathol 2003; 163: 2165-2172.
66. Lim K, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumourigenesis. Cancer Cell 2005; 7: 533-545.
67. Gill, G.N.: US58044212 (1998).
68. Challita-Eid PM, Jakobovitis A, Levin H, Hubert RS, Faris M, Afar DEH, Raitano AB.: CA2420543/WO0216598/WO0216593/EP1311675 (2002).
69. Montalbano J, Jin W, Sheikh MS, Huang Y. RBEL1 is a novel gene that encodes a nucleocytoplasmic Ras superfamily GTP-binding protein and is overexpressed in breast cancer. J Biol Chem 2007; 282: 37640-37649.
70. Goodison S, Yuan J, Sloan D, et al. The rhogap protein dlc-1 functions as a metastasis suppressor in breast cancer cells. Cancer Res 2005; 65: 6042-6053.
71. Hall JM, Korach KS: Stromal cell-derived factor 1, a novel target of estrogen receptor action, mediates the mitogenic effects of estradiol in ovarian and breast cancer cells. Mol Endocrinol 2003, 17:792-803.
72. Prest SJ, May FE, Westley BR. The estrogen-regulated protein, TFF1, stimulates migration of human breast cancer cells. FASEB J 2002, 16: 592-594.
73. Schnaeker EM, Ossig R, Ludwig T, et al. Microtubule-dependent matrix metal-loproteinase-2/matrix metalloproteinase-9 exocytosis: prerequisite in human melanoma cell invasion. Cancer Res 2004; 64: 8924-8931.
74. Delcroix JD, Valletta JS, Wu C, Hunt SJ, Kowal AS, Mobey WC. NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. Neuron 2003; 39: 69-84.
75. Weaver AM. Invadopodia. Specialized cell structures for cancer invasion. Clin Exp Metastasis 2006; 23: 97-105.
76. Hugel B, Martinez MC, Kunzelmann C, Freyssinet JM. Membrane microparticles: two sides of the coin. Physiology 2005; 20: 22-27.
77. Ratajczak J, Wysoczynski M, Hayen F, Janowska-Wieczorek A, Ratajczak MZ. Membrane-derived microvesicles: important and underappreciated mediators of cell-to-cell communication. Leukaemia 2006; 20; 1487-1495.
78. Rozmyslowicz T, Majka M, Kijowski J, et al. Platelet- and megakaryocyte-dervied microparticles transfer CXCR4 receptor to CXCR4-null cells and make them susceptible to infection by X4HIV. AIDS 2003; 17: 33-42.
79. Ratajczak J, Miekus K, Kucia M, Zhang J, Reca R, Dvorak P, Ratajczak MZ. Embryonic stem cell-derived microvesicles reprogram hematopoetic progenitors: evidence for horizontal transfer of mRNA and protein delivery. Leukaemia 2006; 20; 847-856.
80. Baj-Krzyworzeka M, Szatanek R, Weglarczyk K, et al. Tumour-derived microvesicles carry several surface determinants and mRNA of tumour cells and transfer some of these determinants to monocytes. Cancer Immunol Immunother 2006; 55: 808-818.
81. Laulagnier K, Motta C, Hamdi S, et al. Mast cell- and dendritic cell-derived exosomes display a specific lipid composition and an unusual membrane organization. Biochem J 2004; 380: 161-171. 84 Taylor DD, Black PH. Shedding of plasma membrane fragments. Neoplastic and developmental importance. Dev Biol (N. Y. 1985) 1986; 3: 33-57.
82. Andre F, Schartz NE, Movassagh M, et al. Malignant effusions and immunogenic tumour-derived exosomes. Lancet 2002; 360: 295-305.
83. Dolo V, Ginestra A, Cassara D, et al. Selective localization of matrix metalloproteinase 9, beta1 integrins, and human lymphocyte antigen class I molecules on membrane vesicles shed by 8701-BC breast carcinoma cells. Cancer Res 1998; 58: 4468-4474.
84. Ginestra A, La Placa MD, Saladino F, Cassara D, Nagase H, Vittorelli ML. The amount and proteolytic content of vesicles shed by human cancer cell lines correlates with their in vitro invasiveness. Anticancer Res 1998; 18: 3433-3437.
85. Graves LE, Ariztia EV, Navari JR, Matzel HJ, Stack MS, Fishman DA. Proinvasive properties of ovarian cancer ascites-derived membrane vesicles. Cancer Res 2004; 64: 7045-7049.
86. Kim CW, Lee HM, Lee TH, Kang C, Kleinman HK, Gho YS. Extracellular membrane vesicles from tumour cells promote angiogenesis via sphingomyelin. Cancer Res 2002; 62: 6312-6317.
87. Kim JW, Wieckowski E, Taylor DD, Reichert TE, Watkins S, Whiteside TL. Fas ligand-positive membranous vesicles isolated from sera of patients with oral cancer induce apoptosis of activated T lymphocytes. Clin Cancer Res 2005; 11: 1010-1020.
88. Kimberly RP, Grizzle WE, Zhang HG. Murine mammary carcinoma exosomes promote tumour growth by suppression of NK cell function. J Immunol 2006; 176: 1375-1385.
89. Koga K, Matsumoto K, Akiyoshi T, et al. Purification, characterization and biological significance of tumour-derived exosomes. Anticancer Res 2005; 25: 3703-3707.
90. Lu J, May L, Lhotak V, et al. Oncogenic events regulate tissue factor expression in colorectal cancer cells: implications for tumour progression and angiogenesis. Blood 2005; 105(4): 1734-1741.
91. Yu X, Harris SL, Levine AL. The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res 2006; 66: 4795-4801.
92. Bard MP, Hegmans JP, Hemmes A, et al. Proteomic Analysis of exosomes isolated from human malignant pleural effusions. Am J Respir Cell Mol Biol 2004; 31: 114-121.
93. Simon SM, Schindler M. Cell biological mechanisms of multidrug resistance in tumours. Proc Natl Acad Sci 1994; 91: 3497-3504.
94. Sehested M, Skovsgaard T, van Deurs B, Winther-Nielson H. Increase in nonspecific adsorptive endocytosis in anthracycline-and vinca alkaloid-resistant Ehrlich ascites tumour cell lines. J Natl Cancer Inst 1987; 78: 171-179.
95. Shedden K, Xie XT, Chandaroy P, Chang YT, Rosania GR. Expulsion of small molecules in vesicles shed by cancer cells: association with gene expression and chemosensitivity profiles. Cancer Res 2003; 63: 4331-4337.
96. Ifergan I, Scheffer GL, Assaraf YG. Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance. Cancer Res 2005; 65: 10952-10958.
97. Gong Y, Duvvuri M, Duncan MB, Liu J, Krise JP. Niemann-Pick C1 protein facilitates the efflux of the anticancer drug daunorubicin from cells according to a novel vesicle-mediated pathway. J Pharm Exp Ther 2006; 316: 242-247.
98. Shan J, Mason JM, Yuan L, et al. Rab6c, a new member of the Rab gene family, is involved in drug resistance in MCF-7/AdrR cells. Gene 2000; 257: 67-75.
99. Shan J, Yuan L, Budman DR, Xu HP. WTH3, a new member of the Rab6 gene family, and multidrug resistance. Biochim. Biophys. Acta 2002; 1589: 112-123.
100. Murakami T, Shibuya I, Ise T, et al. Elevated expression of vacuolar proton pump genes and cellular PH in cisplatin resistance. Int J Cancer 2001 93: 869-874.
101. Carew JS, Nawrocki ST, Krupnik YV, et al. Targeting endoplasmic reticulum protein transport: a novel strategy to kill malignant B cells and overcome fludarabine resistance in CLL. Blood 2006; 107(1): 222-231.
102. Raghunand N, Martínez-Zaguilán R, Wright SH, Gillies RJ. pH and drug resistance. II. Turnover of acidic vesicles and resistance to weakly basic chemotherapeutic drugs. Biochem Pharmacol 1999; 57: 1047-1058.
103. Morelli AE, Larregina AT, Shufesky WJ, et al. Endocytosis, intracellular sorting, and processing of exosomes by dendritic cells. Blood 2004; 104: 3257-3266.
104. Gould SJ, Booth AM, Hildreth JEK. The Trojan exosome hypothesis. PNAS 2003; 100: 10592-10597.
105. Watanabe M, Fiji HDG, Guo L, et al. Inhibitors of protein geranylgeranyltransferase-I and Rab geranylgeranyltransferase identified from a library of allenoate derived compounds. J Biol Chem 2008; 283: 9571-9579.
106. Zhang HG, Kim H, Liu C, et al. Curcumin reverses breast tumour exosomes mediated immune suppression of NK cell tumour cytotoxicity. Biochim Biophys Acta 2007; 1773: 1116-11123.
107. Iero M, Valenti R, Huber V, Filipazzi P, Parmiani G, Fais S, Rivoltini L. Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 2008; 15: 80-88.
108. McCluskey, A., Robinson, P.J., Hill, T.A: WO05049009 (2005).
109. McCluskey, A., Robinson, P.J., Hill, T.A: US20070225363 (2007
110. Fisher, J., Lorens, J., Payan, D., Rossi, A.: US20056897031 (2005).
111. Luo, Y., Shen, M., Lorens, J., Anderson, D., Fisher, J., Huang, C.B.: US20036623980 (2003).
112. Lindquist, S.L., Gitler, A.D., Cashikar, A., Cooper, A.A., Haynes, C.M.: WO06073734 (2006).
113. McCluskey, A., Robinson, P.J., Hill, T.A: WO05049009 (2005). 118 Exothera LLC, Delcayre A, Le Perq J. WO07015174 (2007).
114. Trajkovic K, Hsu C, Chiantia S, et al. Ceramide triggers budding of exosome vesicles into multivesicular endosomes. Science 2008; 319: 1244-1247.
115. Barral DC, Ramalho JS, Anders R, et al. Functional redundancy of Rab27 proteins and the pathogenesis of Griscelli syndrome. J Clin Invest 2002; 110: 247-257.
116. Dechering KJ. The transcriptome's drugable frequenters. Drug Discov Today 2005; 10(12): 857-864.
117. Zaman GJ, Michiels PJ, van Boeckel CA. Targeting RNA: new opportunities to address drugless targets. Drug Discov Today 2003; 8(7): 297-306.
118. Nickel W. Unconventional secretory routes: direct protein export across the plasma membrane of mammalian cells. Traffic 2003; 6: 607-614.